Current Report Filing (8-k)
December 07 2022 - 04:02PM
Edgar (US Regulatory)
0001711754 false 0001711754 2022-12-06
2022-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
December 6, 2022
|
INMUNE BIO INC. |
| (Exact
name of registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
| (State
or other jurisdiction |
|
(Commission
File Number) |
|
(IRS
Employer |
| of
incorporation) |
|
|
|
Identification
No.) |
225 NE Mizner Boulevard,
Suite 640,
Boca Raton,
FL
33432
(Address
of Principal Executive Offices) (Zip Code)
(858)964-3720
(Registrant’s
Telephone Number, Including Area Code)
Not Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction
A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mart if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
INMB |
|
The
NASDAQ Stock Market LLC |
Item 8.01. Other
Events.
On
December 6, 2022, INmune Bio Inc. (the “Company”) issued a press
release announcing that the Company has been invited to present data on the
combination of INB03™ and trastuzumab-deruxtecan (TDxd) for
treatment of HER2 positive breast cancer. . A copy of
this press release is attached herewith as Exhibit 99.1.
Item
9.01 Financial statements and Exhibits
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date:
December 7, 2022 |
INMUNE
BIO INC. |
| |
|
| |
By: |
/s/
David Moss |
| |
|
David
Moss |
| |
|
Chief
Financial Officer |
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2023
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2022 to May 2023
